Articles

Diabetologia

, Volume 43, Issue 5, pp 598-608

First online:

Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients

  • U. RollAffiliated withDepartments of Medicine and Microbiology/Immunology, Hormone Research Institute, University of California San Francisco, USA
  • , C. W. TurckAffiliated withHoward Hughes Medical Institute, Department of Medicine and Cardiovascular Research Institute, University of California San Francisco, USA
  • , S. E. GitelmanAffiliated withDepartment of Pediatrics, University of California San Francisco, USA
  • , S. M. RosenthalAffiliated withDepartment of Pediatrics, University of California San Francisco, USA
  • , M. S. NolteAffiliated withDepartment of Medicine, University of California San Francisco, USA
  • , U. MasharaniAffiliated withDepartment of Medicine, University of California San Francisco, USA
  • , A.-G. ZieglerAffiliated withDiabetes Research Institute and Third Medical Department City Hospital Schwabing, Munich, Germany
  • , S. BaekkeskovAffiliated withDepartments of Medicine and Microbiology/Immunology, Hormone Research Institute, University of California San Francisco, USA

Abstract

Aims/hypothesis. Glima 38 is an N-glycated neuroendocrine membrane protein of Mr 38 000, which is recognised by autoantibodies in approximately 20 % of patients with Type I (insulin-dependent) diabetes mellitus. The aim of this study was to characterise the carbohydrate moiety and generate peptide maps of glima 38. Methods. Sera of high immunoreactivity to glima 38 were used to isolate 35-S methionine-labelled protein from βTC-3 cells and a neuronal cell line GT1.7. Tunicamycin was used to inhibit N-glycation of glima 38 and define the core protein. The carbohydrate moiety was characterised for tunicamycin sensitivity, lectin binding and susceptibility to different endoglycosidases. The protein moiety was subjected to digestion by proteases to define peptide maps. Results. The autoreactive epitopes in glima 38 recognised by Type I diabetic sera are conformational and independent of the carbohydrate moiety. Inhibition of N-glycation of glima 38 in vivo, shows a protein core of Mr 22 000 in both pancreatic β-(βTC3) and neuronal (GT1.7) cell lines. The carbohydrate moieties in the two cell types are distinct but contain a similar amount of terminal sialic acid residues and at least five oligosaccharide chains Glima 38 binds Triticum vulgare and Ricinus communis I lectins. Endoproteinase treatment of the Mr 22 000 core protein results in peptides of Mr 4500 and Mr 20 000 with Lys-C, and peptides of Mr 4 000 and Mr 11 000–12 000 with Glu-C/V8 and Asp-N proteases. Conclusion/interpretation. The biochemical properties of glima 38 define it as a new autoantigen in Type I diabetes and provide a basis for its purification. [Diabetologia (2000) 43: 598–608]

Keywords Type I diabetes immunology autoantibodies target autoantigen 38 000 Mr autoantigen glima 38 proteolytic cleavage peptide mapping lectin binding deglycation.